Thrombosis Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

The Thrombosis Drugs Market is segmented by Drug Class (Factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor, and Other Drug Classes), Disease Type (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, and Other Disease Types), Distribution Channel, and Geography

Market Snapshot

Thrombosis Drugs Market - 3
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

9.0%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

As per the publication of the US Census Bureau in 2018, the population of people aged 65 and above in the United States may increase drastically between 2016 and 2060 period. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million. Also, according to the National Health and Nutrition Examination Survey (NHANES) conducted in 2013–2014, one in every three adults were considered overweight, and about one in thirteen adults were suffering from extreme obesity. The increasing burden of obesity has also changed significantly in the last one decade, globally. Both developed and emerging markets are having significant issues in controlling the associated diseases. The growing consumption of alcohol and tobacco, with overweight and obesity, adds a high risk of developing significant high blood pressure on veins for a large period of life leading to several thrombosis related complications, thus driving this market. Other factors contributing to the growth of this market are increasing the burden of cardiovascular and trauma cases, with the increasing R&D expenditure in the field of hematological disorders.

In treatment by anti-clotting medication, a patient’s blood takes much longer to clot, such as in case of any accidental cuts. Uncontrolled bleeding is a very common side effect of thrombolytic drugs. Another noteworthy side effect of anticoagulants is a stroke. These side effects of thrombosis drugs often demand alternative therapy recommended by doctors to the patients. Thus, it is among the major barrier for the growth of this market over the forecast period. Another factor that may impede the market growth is lack of awareness about the severity of thrombosis.

 

Scope of the Report

As per the scope of the report, thrombosis is considered to be the major source of morbidity and mortality among elderly patients. It has been established that thrombosis is caused, due to certain cardiovascular disorders as a result of old age or obesity. In the current era, there is an increasing burden of geriatric population, along with obesity, due to sedentary lifestyle across developed and emerging markets. This is primarily associated to drive the thrombosis drug business. 

By Drug Class
Factor Xa Inhibitor
Heparin
P2Y12 Platelet Inhibitor
Other Drug Classes
By Disease Type
Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis
Other Disease Types
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Factor Xa Inhibitor Segment is Expected to Register a Significant Growth during the Forecast Years

By drug class, the market has been segmented into factor Xa inhibitor, heparin, P2Y12 platelet inhibitor, and other drug classes. The factor Xa inhibitor is expected to grow during the forecast period, due to the high preference of anti-coagulant drugs. These drugs are basically used for the prevention and treatment of pulmonary embolism and deep vein thrombosis. In addition, increasing focus on the development of low-cost drugs and large patient pool contributes to the growth of thrombosis drugs market.

Thrombosis Drugs Market -2

To understand key trends, Download Sample Report

North America Leads the Thrombosis Drugs Market

North America leads the market, owing to the high prevalence of cardiovascular diseases, the upsurge in the demand for progressive treatment options, early adoption of new technologies, and an increase in the elderly population. Europe and the Asia-Pacific are followed next after North America, owing to the presence of a diversified patient pool, emerging economies, and rise in collaboration of domestic and international companies with campaigns for awareness campaign in these regions, thus driving this market.

Thrombosis Drugs Market - 4

To understand geography trends, Download Sample Report

Competitive Landscape

The thrombosis drugs market is moderately competitive and many of the global players are into the market. For instance, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc., etc. are providing these products across the world.

Major Players

  1. Bayer AG
  2. Boehringer Ingelheim GmbH
  3. Johnson & Johnson
  4. Sanofi SA
  5. Pfizer Inc.

* Complete list of players covered available in the table of contents below

Thrombosis Drugs Market - 5

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Geriatric and Obese Population

      2. 4.2.2 Increasing Burden of Cardiovascular and Trauma Cases

      3. 4.2.3 Increasing Technological Advancements in Hematology

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness about Venous Thromboembolism Conditions

      2. 4.3.2 Side Effects Caused, due to Thrombosis Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Factor Xa Inhibitor

      2. 5.1.2 Heparin

      3. 5.1.3 P2Y12 Platelet Inhibitor

      4. 5.1.4 Other Drug Classes

    2. 5.2 By Disease Type

      1. 5.2.1 Pulmonary Embolism

      2. 5.2.2 Atrial Fibrillation

      3. 5.2.3 Deep Vein Thrombosis

      4. 5.2.4 Other Disease Types

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East & Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East & Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Aspen Pharmacare Holdings Limited

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Bayer AG

      4. 6.1.4 Boehringer Ingelheim GmbH

      5. 6.1.5 Bristol-Myers Squibb

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information